DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation

Information source: Samsung Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Atrial Fibrillation

Intervention: Propafenone (Drug); Dronedarone (Drug)

Phase: N/A

Status: Completed

Sponsored by: Samsung Medical Center

Official(s) and/or principal investigator(s):
Young Keun On, MD, PhD, Principal Investigator, Affiliation: Samsung Medical Center

Summary

the purpose of this study is to compare the ability of propafenone and dronedarone to maintain sinus rhythm after DC cardioversion

Clinical Details

Official title: Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation After DC Cardioversion

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: recurrence of atrial fibrillation

Detailed description: Atrial fibrillation is the most common arrhythmia requiring continuous therapy. Conversion to and maintenance of sinus rhythm is important. Propafenone and dronedarone has been used as treatment for maintenance of sinus rhythm after DC cardioversion. But there are no direct comparison study. The purpose of this study is to compare the ability of propafenone and dronedarone to maintain sinus rhythm after DC cardioversion.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- a patient with persistent atrial fibrillation who received successful DC

cardioversion Exclusion Criteria:

- prior amiodarone use

- NYHA class III or IV heart failure

- Left ventricular ejection fraction < 35%

- second or third AV block

- sick sinus syndrome

- heart rate < 50 beat per minute

- myocardiac infarction within 3 months

- pregnant women

- severe hepatic dysfunction

- QT prolongation > 500ms or PR interval > 180ms

- history of hypersensitivity for drug

Locations and Contacts

Cardiac and Vascular Center, Seoul 135-710, Korea, Republic of
Additional Information

Starting date: May 2011
Last updated: November 17, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017